Please ensure Javascript is enabled for purposes of website accessibility

Natus Medical Inc: This BABY Has Some Growing Pains

By Brian Orelli, PhD - Apr 27, 2017 at 4:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It was a rough quarter for the medical device and services company.

Natus Medical (NTUS 1.41%) reported a rough first quarter on Wednesday, with profits from its legacy business falling, while newly acquired Otometrics added quite a bit of revenue growth, but little profit.

Natus Medical results: The raw numbers


Q1 2017

Q1 2016

Year-Over-Year Change


$124.7 million

$87.3 million


Income from operations

$1.4 million

$11.2 million


Earnings per share




Data source: Natus Medical.

Mom and dad with newborn in a hospital room

Image source: Getty Images.

What happened with Natus Medical this quarter?

  • The revenue growth came from Otometrics, which became part of Natus Medical in the beginning of January. The new segment, which sells hearing-diagnostic, hearing-aid fitting, and balance-assessment products, was "slightly" profitable, so it didn't contribute much to the earnings line.
  • Management noted that it was the first time that Otometrics was profitable in the first quarter, so it's headed in the right direction under its new leadership. Otometrics is on its way to achieving a 10% adjusted operating profit margin this year with a goal of expanding that to 20% next year.
  • Management blamed the lack of revenue growth from the legacy business on lower birth rates and lower reimbursement for hearing screening done by Peloton, its hearing-services business.
  • The lower profitability was caused by continued costs to deal with the FDA warning letter at its facility in Seattle, which Natus Medical hopes to be resolved next year.

What management had to say

Management has a plan to increase margins at Peloton by adding additional services that hospitals might want to outsource, explained Jonathan Kennedy, Natus Medical's CFO, EVP, and general manager of newborn care:

To combat that, we've just introduced, this last quarter, a new service where we're going to screen the babies [for hearing], but then also there's an additional test that we do that we'll charge the hospital for just a flat fee per baby. So that will expand basically our offering and increase our margin there.

In hospitals where there aren't enough births, or reimbursement isn't high enough to produce a profit by offering outsourcing to the hospitals, Natus has the ability to switch back to just selling its hearing screener and make money from disposables. Kennedy noted: "We have to look at the overall profitability of that business and when it makes sense to pursue a service model or pursue a hardware-and-supplies model, and that's going to be in the hospital by hospital case."

Looking forward

Natus hit a triple whammy of lower birth rates, an ongoing warning letter that's reducing revenue and increasing costs, and a lower reimbursement for Peloton. It can't really do anything about the birth rates, and the warning letter should be resolved next year, which leaves increasing margins at Peloton as the most critical factor investors should be watching.

Fortunately, management made the smart move of acquiring Otometrics, which diversifies the company away from newborn screening and offers an opportunity to grow earnings by expanding the segment's operating profit margin.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Natus Medical Incorporated Stock Quote
Natus Medical Incorporated
$33.11 (1.41%) $0.46

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.